Supriya Lifescience Ltd
Supriya Lifescience Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #26 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Supriya Lifescience targets a revenue of Rs. Supriya Lifescience targets a revenue of around Rs.
From Supriya Lifescience Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Supriya Lifescience targets a revenue of Rs. 1,000 crores by FY '27, reflecting strong demand and robust product pipeline.
- The company expects a CAGR growth of about 20% year-on-year beyond FY '27, supported by new products and capacity expansions.
- Q1 FY '27 revenue was Rs. 190 crores, showing 31% YoY growth despite water scarcity issues.
- Growth is anticipated to accelerate in the second half of FY '27 due to scaling-up of liquid anesthetic products, cardiovascular drugs, and launch of contrast media products.
- Continued addition of new products, new therapy verticals, and CMO-CDMO collaborations at API and formulation levels will support sustained growth.
2 more points from Supriya Lifescience Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Patalganga Facility Investment: Phase-1 CapEx earmarked at around Rs. 200 crores, including two API/advanced intermediate blocks and two formulation blocks. Construction started with boundary walls already underway. API block prioritized initially due to nearing capacity exhaustion at the Lote site. Formulation blocks to be developed phase-wise (Page 4, 5, 12).
- Isambe Project: Initial phase CapEx estimated at Rs. 200 crores with potential for larger investment in subsequent phases (Page 17).
- Ambernath Facility: Depreciation expected at Rs. 14-15 crores annually; facility recently started contributing to revenue and scheduled for EU audit in November (Page 10, 12).
2 more points from Supriya Lifescience Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is scaling its CDMO-CMO business with promising progress.
- They are very close to signing a term sheet for a large anesthetic CDMO contract, expected to be announced next quarter.
- Qualification work and quality approvals for this contract are largely completed.
- New product launches, including anesthetic liquids and cardiovascular drugs, are expected to contribute to order growth.
- The company anticipates a robust product pipeline supporting sustained demand across various therapeutic segments.
2 more points from Supriya Lifescience Ltd's call on order book
Create a free account to keep reading this call
Supriya Lifescience Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹277 Cr, net profit ₹74 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Supriya Lifescience Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Supriya Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Supriya Lifescience Ltd Q1 FY27 results?
Supriya Lifescience targets a revenue of Rs. Supriya Lifescience targets a revenue of around Rs.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 35.9 with a market cap of ₹7,128 Cr. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
Patalganga Facility Investment: Phase-1 CapEx earmarked at around Rs.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.